Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Set for April 2, 2024

Seattle-based biotechnology company, Adaptive Biotechnologies Corporation (ADPT), has recently announced that it will be hosting a business update conference call and webcast on April 2, 2024. The event will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time and can be accessed through the “Investors” section of their website at The webcast will also be archived for replay within 24 hours.

Adaptive Biotechnologies believes that the adaptive immune system has the potential to revolutionize disease diagnosis and treatment, but its complexity has limited its full utilization. With a focus on translating the genetics of the adaptive immune system into clinical products, the company aims to decode and leverage its power with scale, precision, and speed. Collaborating with biopharmaceutical companies, Adaptive Biotechnologies informs drug development and develops clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine.

Their products and clinical pipeline are designed to diagnose, monitor, and treat diseases like cancer, autoimmune disorders, and infectious diseases with personalized immune-driven clinical products for each patient in mind. For investors interested in learning more about Adaptive Biotechnologies’ mission and future plans, they can contact the company’s Vice President of Investor Relations, Karina Calzadilla at 201-396-1687 or via email at . Media inquiries can be directed to the Associate Director of Corporate Communications, Erica Jones at 206-279-2423 or via email at media@adaptivebiotech

By Samantha Johnson

As a content writer at, I craft engaging and informative articles that aim to captivate readers and provide them with valuable insights. With a background in journalism and a passion for storytelling, I thoroughly enjoy delving into diverse topics, conducting research, and producing compelling content that resonates with our audience. From breaking news pieces to in-depth features, I strive to deliver content that is both accurate and engaging, constantly seeking to bring fresh perspectives to our readers. Collaborating with a talented team of editors and journalists, I am committed to maintaining the high standards of journalism upheld by our publication.

Leave a Reply